Cargando…
Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment
Denosumab is a humanized monoclonal antibody that binds RANKL to inhibit osteoclast activity. It is indicated for the prevention of skeletal-related events (SRE) in patients with solid tumors who have bone metastasis and in patients with multiple myeloma. Hypocalcemia is one of the known side effect...
Autores principales: | Gouli, Sugam, Wang, Jimmy, Patel, Anush, Allerton, Jeffery |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427738/ https://www.ncbi.nlm.nih.gov/pubmed/34522524 http://dx.doi.org/10.7759/cureus.17046 |
Ejemplares similares
-
Diagnosis and Management of Denosumab-Induced Hypocalcemia and Hypophosphatemia in the Setting of Metastatic Prostate Cancer
por: Flood, Michael G, et al.
Publicado: (2022) -
Severe Refractory Hypocalcemia Caused by Denosumab
por: Dadana, Sriharsha, et al.
Publicado: (2023) -
The Calcium Culprit: A Case of Denosumab-induced Hypocalcemia
por: Kalayanamitra, Ricci, et al.
Publicado: (2019) -
Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
por: Mehmood, Hassan, et al.
Publicado: (2021) -
Denosumab Induced Severe Hypocalcemia in a Patient With Metastatic Prostate Cancer
por: Naher, Kamrun, et al.
Publicado: (2021)